View Older Stories View More Recent Stories
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
-
Form SCHEDULE 13G C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Rani Therapeutics adds two directors, closes $60.3 million funding
-
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
-
Rani Therapeutics raises $60.3 million in oversubscribed private placement
-
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
-
VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform
-
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
-
Rani Therapeutics raises $60.3 million in oversubscribed private placement
-
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
-
Rani Therapeutics secures $1.085 billion collaboration deal with Chugai
-
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurre
-
Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
C4 Therapeutics prices $125 million stock offering
-
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
-
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
-
Radence expands concierge membership to detect and prevent disease before it occurs
-
Form SCHEDULE 13G PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the Europ
-
T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the Europ
-
Jade Biosciences raises $135 million in private placement
-
Jade Biosciences Announces $135 Million Private Placement
-
Form SCHEDULE 13D SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ovid Therapeutics raises up to $175 million in private placement
-
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
-
Palisade Bio closes $138 million public offering to fund drug trial
-
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
-
Form SCHEDULE 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Drugmakers pressured with Trump tariffs after price‑cut talks faltered
-
Form SCHEDULE 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
-
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
-
ARS Pharmaceuticals secures $250 million loan facility for neffy expansion
-
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
-
Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
-
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune
-
ProofPilot Announces Inaugural CORE Symposium for Clinical Operations Leaders
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
Form SCHEDULE 13D/A Mineralys Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Belite Bio raises up to $275 million in private placement
-
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
-
CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma
-
Form SCHEDULE 13G Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
